Market Cap 3.17B
Revenue (ttm) 517.15M
Net Income (ttm) 66.35M
EPS (ttm) N/A
PE Ratio 27.68
Forward PE 33.31
Profit Margin 12.83%
Debt to Equity Ratio 0.00
Volume 742,300
Avg Vol 947,212
Day's Range N/A - N/A
Shares Out 79.79M
Stochastic %K 76%
Beta 1.89
Analysts Strong Sell
Price Target $46.90

Company Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was f...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 243 6300
Fax: 650 243 6388
Address:
6000 Shoreline Court, Suite 300, South San Francisco, United States
BillionerOfKing
BillionerOfKing May. 11 at 1:16 PM
$VCYT Current Stock Price: $40.44 Contracts to trade: $40.0 VCYT May 15 2026 Call Entry: $2.52 Exit: $3.30 ROI: 31% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BioTechHealthX
BioTechHealthX May. 10 at 5:15 PM
$VCYT Veracyte is gaining attention as a precision medicine stock with rising test volume, 21% revenue growth, positive net income, and expanding cancer diagnostics exposure beyond prostate and thyroid testing. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-buy-veracyte-vcyt-shares-today/
0 · Reply
BioTechHealthX
BioTechHealthX May. 10 at 4:21 AM
$ARQT $CDNA $NBIX $VCYT $BHVN These top 5 biotech stocks to buy for May 2026 are not just random healthcare names. With projected EPS growth reaching up to 215%, rising sales expectations, precision medicine exposure, and high-risk, high-reward biotech potential, this list could grab serious investor attention. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-to-buy-with-up-to-215-projected-eps-growth/
0 · Reply
Kool_Aid_Mann
Kool_Aid_Mann May. 8 at 7:53 PM
$VRTX $ALNY $REGN Join MNKD as they approach their May 29th pediatric PDUFA!! This is the one that they have been waiting for for 12 years. Lots of delays, but finally here and likely to be the milestone trigger for a big cash deal with big pharma! On top of that, they just got back the green light for Treprostinil DPI in IPF which had them previously trading over $6 until a spat with their partner UTHR. Now, not only is everything copacetic again, but they have also just announced a new molecule colloboration with bigger potential than Trep, Ralinpag DPI! Big royalty model like $LGND But wait, there's more, there is another PDUFA ahead for them for furoscix on July 26th, that will approve a new auto injector that will make this product best in class and reduce COGs by 70% to create massive profits. And lets not forget that nintedabib DPI just finished 1b and is prime for an upfront cash deal! $VCYT Fireworks ahead, fight the Citadel!
0 · Reply
stockanalysis_
stockanalysis_ May. 5 at 8:34 PM
After Hours Gainers: $EVC $AVTX $SMCI $VCYT $FLYW Download this screener: https://stockanalysis.com/markets/afterhours/gainers/?ref=saveontrading
0 · Reply
PhishTourFunds
PhishTourFunds May. 5 at 8:27 PM
$VCYT Up 16% in AH today 💥
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 8:16 PM
$VCYT Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.36 up 300.00% YoY • Reported revenue of $139.07M up 21.49% YoY • Veracyte raised its 2026 total revenue guidance to $582M to $592M (13%-14% growth) and testing revenue guidance to $570M to $580M (16%-18% growth). Veracyte also raised adjusted EBITDA margin guidance to greater than 26%.
0 · Reply
PhishTourFunds
PhishTourFunds May. 5 at 12:43 AM
$VCYT #RoundTripper Hit $50 before the end of the year 💪
0 · Reply
PhishTourFunds
PhishTourFunds Apr. 22 at 11:22 AM
$VCYT Accumulating while filling the gap on the six month chart
0 · Reply
notreload_ai
notreload_ai Apr. 13 at 4:04 PM
Canaccord says $BHVN is undervalued and could rise on epilepsy trial results. Jefferies likes $CAI and $VCYT , citing strong growth in cancer diagnostics and solid finances. https://notreload.xyz/xy/analysts-turn-bullish-on-biohaven-caris-and-veracyte/
0 · Reply
Latest News on VCYT
Veracyte price target raised to $42 from $40 at Canaccord

2026-05-07T06:56:24.000Z - 6 days ago

Veracyte price target raised to $42 from $40 at Canaccord


Veracyte price target raised to $52 from $48 at UBS

2026-05-07T03:55:46.000Z - 6 days ago

Veracyte price target raised to $52 from $48 at UBS


Veracyte Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 7 days ago

Veracyte Earnings Call Transcript: Q1 2026


Veracyte Announces First Quarter 2026 Financial Results

May 5, 2026, 4:05 PM EDT - 7 days ago

Veracyte Announces First Quarter 2026 Financial Results


Veracyte announces new data at AUA 2026 on Decipher portfolio

2026-04-28T14:12:33.000Z - 14 days ago

Veracyte announces new data at AUA 2026 on Decipher portfolio


Veracyte price target lowered to $40 from $43 at Canaccord

2026-04-20T14:03:18.000Z - 22 days ago

Veracyte price target lowered to $40 from $43 at Canaccord


Veracyte initiated with a Buy at Jefferies

2026-04-12T23:52:05.000Z - 4 weeks ago

Veracyte initiated with a Buy at Jefferies


Veracyte price target lowered to $45 from $50 at Guggenheim

2026-03-30T11:52:33.000Z - 6 weeks ago

Veracyte price target lowered to $45 from $50 at Guggenheim


Veracyte Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 10:40 AM EDT - 2 months ago

Veracyte Transcript: Leerink Global Healthcare Conference 2026


Veracyte price target lowered to $37 from $48 at Morgan Stanley

2026-03-06T13:27:22.000Z - 2 months ago

Veracyte price target lowered to $37 from $48 at Morgan Stanley


Veracyte reports Q4 EPS 51c, consensus 41c

2026-02-25T22:15:11.000Z - 2 months ago

Veracyte reports Q4 EPS 51c, consensus 41c


Veracyte sees FY26 revenue $570M-$582M, consensus $570.3M

2026-02-25T22:14:18.000Z - 2 months ago

Veracyte sees FY26 revenue $570M-$582M, consensus $570.3M


Veracyte Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 2 months ago

Veracyte Earnings Call Transcript: Q4 2025


Veracyte to Participate in Upcoming Investor Conferences

Feb 19, 2026, 5:00 PM EST - 2 months ago

Veracyte to Participate in Upcoming Investor Conferences


Veracyte Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 12:45 PM EST - 4 months ago

Veracyte Transcript: 44th Annual J.P. Morgan Healthcare Conference


Veracyte sees FY26 revenue $570M-$582M, consensus $565.76M

2026-01-11T22:15:32.000Z - 4 months ago

Veracyte sees FY26 revenue $570M-$582M, consensus $565.76M


Veracyte price target raised to $50 from $45 at Guggenheim

2026-01-05T14:30:21.000Z - 4 months ago

Veracyte price target raised to $50 from $45 at Guggenheim


Veracyte assumed with an Underweight at Morgan Stanley

2025-12-01T21:40:31.000Z - 5 months ago

Veracyte assumed with an Underweight at Morgan Stanley


Veracyte Transcript: Stephens Annual Investment Conference

Nov 20, 2025, 12:00 PM EST - 6 months ago

Veracyte Transcript: Stephens Annual Investment Conference


Veracyte Transcript: Jefferies London Healthcare Conference 2025

Nov 20, 2025, 6:30 AM EST - 6 months ago

Veracyte Transcript: Jefferies London Healthcare Conference 2025


Veracyte Transcript: Wolfe Research Healthcare Conference 2025

Nov 17, 2025, 10:00 AM EST - 6 months ago

Veracyte Transcript: Wolfe Research Healthcare Conference 2025


Veracyte price target raised to $40 from $28 at Morgan Stanley

2025-11-11T13:05:54.000Z - 6 months ago

Veracyte price target raised to $40 from $28 at Morgan Stanley


Veracyte rises 21.4%

2025-11-05T17:06:02.000Z - 6 months ago

Veracyte rises 21.4%


Veracyte Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 6 months ago

Veracyte Earnings Call Transcript: Q3 2025


Veracyte Announces Third Quarter 2025 Financial Results

Nov 4, 2025, 4:05 PM EST - 6 months ago

Veracyte Announces Third Quarter 2025 Financial Results


Veracyte Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 9 months ago

Veracyte Earnings Call Transcript: Q2 2025


Veracyte Announces Second Quarter 2025 Financial Results

Aug 6, 2025, 4:05 PM EDT - 9 months ago

Veracyte Announces Second Quarter 2025 Financial Results


Veracyte Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Veracyte Earnings Call Transcript: Q1 2025


Veracyte Announces First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 1 year ago

Veracyte Announces First Quarter 2025 Financial Results


Veracyte Earnings Call Transcript: Q4 2024

Feb 24, 2025, 4:30 PM EST - 1 year ago

Veracyte Earnings Call Transcript: Q4 2024


Veracyte Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 2:45 PM EST - 1 year ago

Veracyte Transcript: UBS Global Healthcare Conference 2024


Veracyte Earnings Call Transcript: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Veracyte Earnings Call Transcript: Q3 2024


Veracyte Announces Third Quarter 2024 Financial Results

Nov 6, 2024, 4:05 PM EST - 1 year ago

Veracyte Announces Third Quarter 2024 Financial Results


Veracyte Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Veracyte Earnings Call Transcript: Q2 2024


Veracyte Announces Second Quarter 2024 Financial Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces Second Quarter 2024 Financial Results


Veracyte Earnings Call Transcript: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

Veracyte Earnings Call Transcript: Q1 2024


Veracyte Announces First Quarter 2024 Financial Results

May 7, 2024, 4:05 PM EDT - 2 years ago

Veracyte Announces First Quarter 2024 Financial Results


BillionerOfKing
BillionerOfKing May. 11 at 1:16 PM
$VCYT Current Stock Price: $40.44 Contracts to trade: $40.0 VCYT May 15 2026 Call Entry: $2.52 Exit: $3.30 ROI: 31% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BioTechHealthX
BioTechHealthX May. 10 at 5:15 PM
$VCYT Veracyte is gaining attention as a precision medicine stock with rising test volume, 21% revenue growth, positive net income, and expanding cancer diagnostics exposure beyond prostate and thyroid testing. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-buy-veracyte-vcyt-shares-today/
0 · Reply
BioTechHealthX
BioTechHealthX May. 10 at 4:21 AM
$ARQT $CDNA $NBIX $VCYT $BHVN These top 5 biotech stocks to buy for May 2026 are not just random healthcare names. With projected EPS growth reaching up to 215%, rising sales expectations, precision medicine exposure, and high-risk, high-reward biotech potential, this list could grab serious investor attention. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-to-buy-with-up-to-215-projected-eps-growth/
0 · Reply
Kool_Aid_Mann
Kool_Aid_Mann May. 8 at 7:53 PM
$VRTX $ALNY $REGN Join MNKD as they approach their May 29th pediatric PDUFA!! This is the one that they have been waiting for for 12 years. Lots of delays, but finally here and likely to be the milestone trigger for a big cash deal with big pharma! On top of that, they just got back the green light for Treprostinil DPI in IPF which had them previously trading over $6 until a spat with their partner UTHR. Now, not only is everything copacetic again, but they have also just announced a new molecule colloboration with bigger potential than Trep, Ralinpag DPI! Big royalty model like $LGND But wait, there's more, there is another PDUFA ahead for them for furoscix on July 26th, that will approve a new auto injector that will make this product best in class and reduce COGs by 70% to create massive profits. And lets not forget that nintedabib DPI just finished 1b and is prime for an upfront cash deal! $VCYT Fireworks ahead, fight the Citadel!
0 · Reply
stockanalysis_
stockanalysis_ May. 5 at 8:34 PM
After Hours Gainers: $EVC $AVTX $SMCI $VCYT $FLYW Download this screener: https://stockanalysis.com/markets/afterhours/gainers/?ref=saveontrading
0 · Reply
PhishTourFunds
PhishTourFunds May. 5 at 8:27 PM
$VCYT Up 16% in AH today 💥
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 8:16 PM
$VCYT Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.36 up 300.00% YoY • Reported revenue of $139.07M up 21.49% YoY • Veracyte raised its 2026 total revenue guidance to $582M to $592M (13%-14% growth) and testing revenue guidance to $570M to $580M (16%-18% growth). Veracyte also raised adjusted EBITDA margin guidance to greater than 26%.
0 · Reply
PhishTourFunds
PhishTourFunds May. 5 at 12:43 AM
$VCYT #RoundTripper Hit $50 before the end of the year 💪
0 · Reply
PhishTourFunds
PhishTourFunds Apr. 22 at 11:22 AM
$VCYT Accumulating while filling the gap on the six month chart
0 · Reply
notreload_ai
notreload_ai Apr. 13 at 4:04 PM
Canaccord says $BHVN is undervalued and could rise on epilepsy trial results. Jefferies likes $CAI and $VCYT , citing strong growth in cancer diagnostics and solid finances. https://notreload.xyz/xy/analysts-turn-bullish-on-biohaven-caris-and-veracyte/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 14 at 3:29 AM
$VCYT RSI: 37.53, MACD: -1.6234 Vol: 1.88, MA20: 35.02, MA50: 38.22 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 1:44 AM
$VCYT Current Stock Price: $35.07 Contracts to trade: $35.0 VCYT Mar 20 2026 Call Entry: $0.45 Exit: $0.69 ROI: 52% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ZacksResearch
ZacksResearch Feb. 26 at 4:53 PM
$VCYT just delivered a clean beat — and the market noticed 🚀 Q4 earnings jumped 47% year over year, revenues climbed 18.5%, margins improved, and the company beat estimates across the board. Shares are already rising after hours — that’s what strong execution looks like. See what’s driving the momentum and whether it can continue 👉 https://www.zacks.com/stock/news/2876043/veracyte-q4-earnings-beat-estimates-revenues-grow-yy-stock-rises?cid=sm-stocktwits-2-2876043-teaser-35320&ADID=SYND_STOCKTWITS_TWEET_2_2876043_TEASER_35320
0 · Reply
ZacksResearch
ZacksResearch Feb. 26 at 3:53 PM
$VCYT gains after Q4 earnings beat — what's fueling the momentum? 🚀 Veracyte's Q4 EPS of 53 cents soared past estimates by 30.06%, with revenues climbing 18.5% YoY, driven by Decipher and Afirma growth of 27% and 16%, respectively. Discover the full earnings breakdown here 👉 https://www.zacks.com/stock/news/2876043/veracyte-q4-earnings-beat-estimates-revenues-grow-yy-stock-rises?cid=sm-stocktwits-2-2876043-body-35321&ADID=SYND_STOCKTWITS_TWEET_2_2876043_BODY_35321
0 · Reply
PhishTourFunds
PhishTourFunds Feb. 26 at 2:31 AM
$VCYT Up over 50% from here
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 25 at 9:16 PM
$VCYT Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.52 up 642.86% YoY • Reported revenue of $140.64M up 18.55% YoY • Veracyte is reiterating 2026 total revenue guidance of $570M to $582M, representing 10% to 13% growth, with adjusted EBITDA margin expected to be approximately 25%.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 22 at 11:04 PM
$DNA at $9 seeing low volume, while $VCYT trading at $36 with slightly above-average volume. VCYT showing 300% more strength compared to DNA. Are investors favoring established players over smaller ones in the Genomics space?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 3:56 PM
$VCYT RSI: 39.79, MACD: -1.4563 Vol: 1.90, MA20: 37.34, MA50: 40.68 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BioTechHealthX
BioTechHealthX Feb. 8 at 5:05 PM
$VCYT Veracyte (NASDAQ:VCYT) is emerging as a top genomic diagnostics stock as demand for precision cancer testing rises in 2026. Here’s what’s driving the story, why the platform looks scalable, and what investors are watching next. https://biotechhealthx.com/biotech-news/is-it-still-safe-to-invest-in-veracyte-vcyt/
0 · Reply
BBraggHillBoys
BBraggHillBoys Feb. 3 at 9:19 PM
$VCYT awful
0 · Reply